Translate this page into:
Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria
Address for correspondence: Dr. Venkatesh Rangarajan, Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Dr. Borges Road, Parel, Mumbai - 400 012, Maharashtra, India. E-mail: drvrangarajan@gmail.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Introduction:
Targeted therapeutic agents are indicated in metastatic lung cancers. These being receptor specific therapies, manifestation of response can be best assessed by estimating the metabolic activity of tumor, rather than the size. This retrospective analysis studied metabolic and morphological response on Positron Emission Tomography (PET) and Computed Tomography (CT), respectively to these agents.
Materials and Methods:
Thirty-one patients (23 males, 8 females with an age range of 42–77 years) with Epidermal Growth Factor Receptor (EGFR) positive metastatic lung cancer on Gefitinib, who underwent PET/CT, at baseline and at 4–6 weeks, were assessed by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 and European Organization for Research and Treatment of Cancer (EORTC) criteria.
Results:
Concordance between RECIST 1.1 and EORTC was seen in 26 (83.7%) patients. Discordance was seen in 5 (16.3%) patients. In patients with discordance, the results were confirmed by follow-up imaging. Metabolic EORTC criteria changed the disease status from stable disease to partial response (3 out of 5) and progressive disease (2 out of 5) in these five patients.
Conclusions:
Metabolic criteria using PET/CT could accurately predict response as well as disease progression early in the course of targeted therapy, compared to morphologic criteria. In addition, early metabolic response assessment can predict refractoriness of therapy.
Keywords
Computed Tomography
Epidermal growth factor receptor
European organization for research and treatment of cancer
Gefitinib
Lung cancer
Response
Response evaluation criteria in solid tumors
Fluoro-deoxy glucose positron emission tomography
INTRODUCTION
PET/CT is the recommended modality for staging of lung cancers. Standard approach towards patients with metastatic lung cancers is palliative oral chemotherapy with targeted agents. Treatment response to these agents is routinely assessed by comparing baseline and post-treatment CT scans, based on Response Evaluation Criteria In Solid Tumors ([RECIST] 1.1) criteria. However, these being receptor specific therapies, manifestation of response can be best assessed by estimating the metabolic activity of tumor, rather than the size. Based on this principle, we aimed at assessing the treatment response on metabolic imaging using FDG PET and comparing it with morphological criteria on CT.
MATERIALS AND METHODS
Patients with metastatic non small cell lung carcinoma (NSCLC) of lung on targeted therapy who were referred to our department for a PET CT study prior to start of treatment and for a response evaluation after 4–6 weeks, between June 2010 and June 2013 were included in this retrospective evaluation. Written informed consent was obtained from all patients.
Patient selection
31 patients (23 males, 8 females) with metastatic (NSCLC) of lung who tested positive for epidermal growth factor receptor (EGFR) were included. These patients received EGFR tyrosine kinase (TK) inhibitor Gefitinib, 250 mg, orally. Independent evaluation was done by - contrast-enhanced CT component of PET/CT and PET component of fused 18 F-FDG PET/CT studies, at baseline and at 4–6 weeks post-therapy. Patient Characteristics are given in Table 1.
Molecular analysis
EGFR mutation diagnostics were performed in all patients with samples suitable for molecular analysis.
Patient preparation
Patients were asked to fast for 4–6 h prior to the study and blood glucose levels were checked and confirmed to be <150 mg/dl. The studies were performed 60–90 min following intravenous administration of 5 MBq/kg of 18F-FDG.
Image acquisition protocol
Imaging was performed on a Discovery ST PET-CT system (GE Medical), equipped with a 16 slice CT scanner with a dedicated PET (BGO crystal, dimensions 3.8 mm × 3.8 mm × 3.8 cm). CT was performed over 5 to 8 eight bed positions from skull base to mid-thigh. CT parameters included 140 kV, 110–210 mA, 0.8 s/rotation, pitch of 1.75:1, field of view [FOV] of 50 cm, length of scan 1.0–1.6 m, 0.625 spatial resolution and slice thickness of 3.75 mm. Intravenous and oral contrast was routinely administered in all patients, after confirming the serum creatinine levels. PET data was acquired sequentially in the same anatomic locations with 15.4 cm axial FOV acquired in 3D (three-dimensional) mode with 3 min/bed position.
Image reconstruction and interpretation
Images reconstruction was done using a standard reconstruction algorithm with ordered subset expectation maximization (OSEM). Image fusion was performed using coordinate based fusion software and transferred to the workstation that provided multi-planar reformatted images and displayed PET, CT, and PET-CT fusion images. Images were independently interpreted by a nuclear medicine physician and a radiologist who were blinded to each other's results. CT findings were analyzed using the RECIST 1.1 and the PET findings by European Organization for Research and Treatment of Cancer Criteria (EORTC) criteria.
Response criteria as per RECIST 1.1[1]
Complete response (CR) indicates disappearance of all target lesions, partial response (PR) as 30% or more decrease in sum of diameters of target lesions, progressive disease (PD) as 20% or more increase in sum of diameters of target lesions and also an absolute increase of at least 5 mm and/or appearance of one or more new lesions, stable disease (SD) – who did not qualify for either sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Response criteria as per EORTC criteria[2]
Complete resolution of FDG uptake within the measurable target lesion so that it is indistinguishable from surrounding background, with the appearance of no new lesion, was labeled as complete metabolic response (CMR). Reduction of minimum of 15–25% of standardized uptake value (SUV) max in the target volume in the same lesion as the baseline measurement was grouped under partial metabolic response (PMR). Progressive metabolic disease (PMD) was a more than 25% increase in the SUV max of the FDG uptake or appearance of FDG avid new lesion/s that is/are morphologically typical of cancer. Stable metabolic disease (SMD) was disease which did not qualify for CMR, PMR, or PMD.
RESULTS
31 patients of metastatic lung cancers, on targeted therapy underwent contrast enhanced PET CT were assessed using RECIST 1.1 New RECIST 1.1and EORTC criteria, respectively [Table 2].
Concordance
Concordance [Figure 1] in response to targeted therapy was seen in 26 (83.4%) out of 31 patients, on metabolic and morphological criteria. Of these 26 patients, 4 patients showed PR/PMR, 10 patients showed SD/SMD and 12 patients showed PD/PMD.
Discordance
Discordance in response to targeted therapy was seen in 5 (16.6%) patients.
Of these, three showed SD on RECIST 1.1 and PMR on EORTC criteria. All the three patients showed complete metabolic and morphological regression in metastatic sites, namely in left supraclavicular nodes [Figure 2] in two patients and contralateral nodule in one patient. However, at the primary site, CT images showed no significant change in size – SD on RECIST 1.1. But on corresponding PET images, significant regression was seen in SUV max values – PMR on EORTC criteria. Follow-up imaging either with CT or PET/CT after 2 months showed no further change in disease status.
Two patients showed SD on RECIST 1.1 and PMD on EORTC metabolic criteria. New focal FDG avid marrow lesions [Figure 3] were seen in both these cases, whereas CT images were unremarkable, thus making the disease status as SD on RECIST 1.1 and PMD on EORTC criteria.
Follow-up imaging either with CT or PET/CT after 2 months in these patients showed further metabolic and morphological disease progression.
DISCUSSION
Targeted therapy has evolved as a critical therapeutic strategy in treatment of metastatic NSCLC. TK inhibitors like Gefitinib targeting the EGFR can improve progression-free survival (PFS) and overall survival (OS) in receptor positive patients with these cancers.[345] Moreover, translational studies have shown that 18F-FDG uptake decreased within 2 h in H3255 cell lines having EGFR mutations after incubation with 0.2 mM of Gefitinib. This was due to translocation of glucose transporters from the cell membrane to the cytoplasm. Similar results were seen on 18F-FDG tumor uptake in animal experiments after only two doses of Gefitinib.[6] This forms the molecular basis of the utility of FDG PET for assessing response to targeted therapy, especially in receptor positive lung cancers.
It is well-known that metabolic response demonstrated by FDG PET-CT well precedes the anatomic response and has been well-documented in the existing literature.[7] Metabolic response on PET is manifested by decrease in the glycolytic activity of tumor, whereas anatomic response criteria which are based on size of the tumor, lag weeks and months behind the metabolic response.[8] Conventionally, NSCLC is an FDG avid tumor and PET/CT is routinely indicated for staging this cancer.[910] Hence, metastatic burden can be assessed and depending on EGFR status, metastatic cancers can be subjected to targeted therapy. The clinical end point of the targeted agents is to achieve a prolonged stable disease rather than tumor shrinkage.[11] Thus, lack of progression is associated with good improvement in outcome, even in the absence of partial or complete response.[2] As a result, standard size-based assessment of response to these therapies using RECIST underestimates therapeutic activity. This forms the basis of use of metabolic parameters using PET for treatment response assessment.
Criteria for metabolic response assessment have been evolving and improving – with PET Response Criteria in Solid Tumors (PERCIST) criteria being followed in all recent studies. Skougaard et al. compared EORTC and PERCIST criteria for response assessment in metastatic colorectal cancer, concluding that both criteria gave similar response and survival outcomes with good agreement.[12]
Metabolic response on PET also impacts the survival statistics in patients with metastatic lung cancer; patients with progressive metabolic disease (PMD) on post-treatment PET study showing shorter time to progression and overall survival (OS) compared to patients with SMD or with partial PMR or complete CMR metabolic response.[13] Our data, though in a small cohort of three patients with PMD on FDG PET showed similar results. Further metabolic and morphological progression seen on follow-up imaging.
In addition, early assessment on FDG PET is also a predictor of response to targeted therapy; PMD suggestive of refractoriness of targeted agents in spite of EGFR receptor positivity.[14] Early prediction of therapeutic failure not only warrants change of treatment, but also avoids unnecessary expenditure and potential toxicity.
Our study highlights the utility of metabolic imaging in metastatic lung cancers, not only for treatment effectiveness of therapy, but also for early assessment of refractoriness.
Though the number of patients is limited, results obtained warrant further assessment with a larger cohort. Furthermore, in addition to follow-up imaging, survival statistics would make the study more robust.
CONCLUSION
Metabolic criteria using PET/CT could accurately predict response as well as disease progression early in the course of targeted therapy, compared to morphologic criteria on CT scan. Hence, functional imaging with FDG PET provides a more definitive evidence of response to targeted therapy and disease status, unlike conventional anatomical imaging.
Source of Support: Nil.
Conflict of Interest: None declared.
REFERENCES
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228-47.
- [Google Scholar]
- Measurement of clinical and subclinical tumour response using 18F-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.
- [Google Scholar]
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.
- [Google Scholar]
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
- [Google Scholar]
- EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500.
- [Google Scholar]
- Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659-67.
- [Google Scholar]
- The lessons of GIST – PET and PET/CT: A new paradigm for imaging. Oncologist. 2008;13(Suppl 2):8-13.
- [Google Scholar]
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
- [Google Scholar]
- Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-61.
- [Google Scholar]
- PET with (18) F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin. 2003;42:135-44.
- [Google Scholar]
- Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011;17:3304-15.
- [Google Scholar]
- Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J Nucl Med. 2013;54:1026-31.
- [Google Scholar]
- (18) F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011;52:1684-9.
- [Google Scholar]
- Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non – Small-cell lung cancer. Clin Lung Cancer. 2012;13:181-7.
- [Google Scholar]